Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Annals of Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ANNONC/6.SUPPL_3.S49PMID 8616116
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-alpha gene expression and cytotoxicity.

  1994cited by this paper
• Taxol (paclitaxel) in the treatment of lung cancer: the Eastern Cooperative Oncology Group experience.

  1994cited by this paper
• Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.

  1994cited by this paper
• A Phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer

  1994cited by this paper
• The taxoids: paclitaxel and docetaxel.

  1994cited by this paper
• Platinum-based chemotherapy in non-small cell lung cancer: the experience of the European Organization for the Research and Treatment of Cancer.

  1994cited by this paper
• A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Japan Vinorelbine Lung Cancer Study Group.

  1994cited by this paper
• Metastatic non-small cell lung cancer

  1993cited by this paper
• Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer.

  1993cited by this paper
• Polychemotherapy in advanced non small cell lung cancer: a meta-analysis.

  1993cited by this paper
• New directions for chemotherapy in non-small-cell lung cancer.

  1993cited by this paper
• New chemotherapeutic agents in non-small-cell lung cancer.

  1993cited by this paper
• Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results.

  1993cited by this paper
• Chemotherapy of lung cancer.

  1992cited by this paper
• Chemotherapy of Lung Cancer

  1992cited by this paper
• Taxol: the first of the taxanes, an important new class of antitumor agents.

  1992cited by this paper
• A Phase II Study of Navelbine (Vinorelbine) in the Treatment of Non‐Small‐Cell Lung Cancer

  1991cited by this paper
• Symptomatic treatment versus combination chemotherapy for patients with extensive non‐small cell lung cancer

  1991cited by this paper
• A phase II study of days 1 and 8 cisplatin and recombinant alpha‐2B interferon in advanced non‐small cell lung cancer

  1991cited by this paper
• Chemotherapy of non-small cell lung cancer according to disease extent: a meta-analysis of the literature

  1991cited by this paper
• A randomized study of two vindesine plus cisplatin‐containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non‐small cell lung cancer

  1990cited by this paper
• Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.

  1988cited by this paper
• A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.

  1986cited by this paper
• Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V--a randomized comparison of four cisplatin-containing regimens.

  1985cited by this paper

• A dose-finding study with a novel water-soluble formulation of paclitaxel for the treatment of malignant high-grade solid tumours in dogs.

  2013cites this paper
• Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.

  2008cites this paper
• Basic treatment considerations: chemotherapy.

  2004cites this paper
• Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors.

  2004cites this paper
• Therapeutic advances in second-line treatment of advanced non-small-cell lung cancer.

  2004cites this paper
• Usefulness of chest single photon emission computed tomography with technetium-99m methoxyisobutylisonitrile to predict taxol based chemotherapy response in advanced non-small cell lung cancer.

  2003cites this paper
• Predicting Chemotherapy Response to Paclitaxel-Based Therapy in Advanced Non-Small-Cell Lung Cancer with P-Glycoprotein Expression

  2003cites this paper
• Weekly administration of paclitaxel attenuated rectal stenosis caused by multiple peritoneal recurrence 8 years after the resection of gastric carcinoma

  2003cites this paper
• Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer.

  2003cites this paper
• Therapy for stage IIIB and stage IV non-small cell lung cancer.

  2002cites this paper
• Predicting Chemotherapy Response to Paclitaxel-Based Therapy in Advanced Non-Small-Cell Lung Cancer (Stage IIIb or IV) with a Higher T Stage (> T2)

  2002cites this paper
• Weekly paclitaxel in the treatment of metastatic and/or recurrent non-small cell lung cancer.

  2002cites this paper
• Spotlight on Paclitaxel in Non-Small Cell Lung Cancer

  2002cites this paper
• Taxanes for advanced non-small cell lung cancer

  2002cites this paper
• Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.

  2001cites this paper
• Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study

  2001cites this paper
• European perspectives on paclitaxel/platinum-based therapy for advanced non-small cell lung cancer.

  2001cites this paper
• Paclitaxel-Based chemotherapy for non-small cell lung cancer: predicting the response with 99mTc-tetrofosmin chest imaging.

  2001cites this paper
• Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions.

  2001cites this paper
• Taxanes in lung cancer: a review with focus on the European experience.

  2001cites this paper
• New Drugs in the Palliative Chemotherapy of Advanced Non-Small-Cell Lung Cancer

  2001cites this paper
• Paclitaxelic Review of its Use in Non-Small Cell Lung Cancer

  2001cites this paper
• Predicting Chemotherapy Response to Paclitaxel-based Therapy in Non-Small Cell Lung Cancer by Early Technetium-99 m Methoxyisobutylisonitrile Chest Single-Photon-Emission Computed Tomography 1

  2000cites this paper
• Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single-photon-emission computed tomography.

  2000cites this paper
• The role of new agents in advanced non—small–cell lung carcinoma

  2000cites this paper
• Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer.

  1999cites this paper
• Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer.

  1999cites this paper
• Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer

  1999cites this paper
• New Drugs in Lung Cancer

  1999cites this paper
• Paclitaxel, Carboplatin, and G-CSF in Advanced Non-Small-Cell Lung Cancer: A Phase I/II Study

  1998cites this paper
• The Burgeoning Role of Paclitaxel in Advanced Pulmonary Malignancy.

  1998cites this paper
• A phase I/II study of paclitaxel (TAXOL) and concurrent radiotherapy in advanced nonsmall cell lung cancer.

  1997cites this paper
• Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).

  1997cites this paper